Skip to main content
Top
Published in: Annals of Surgical Oncology 12/2008

01-12-2008 | Hepatic and Pancreatic Tumors

Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma

Authors: Shishir K. Maithel, MD, Stephen Maloney, MD, Corrine Winston, MD, Mithat Gönen, PhD, Michael I. D’Angelica, MD, Ronald P. DeMatteo, MD, William R. Jarnagin, MD, Murray F. Brennan, MD, Peter J. Allen, MD

Published in: Annals of Surgical Oncology | Issue 12/2008

Login to get access

Abstract

Background

Staging laparoscopy for patients with radiographically resectable pancreatic adenocarcinoma has been reported to yield an 8–15% finding of unresectable disease. Factors associated with the likelihood of subradiographic unresectable disease have not been clearly defined.

Methods

A prospectively maintained pancreatic database was reviewed and patients were identified who underwent staging laparoscopy for radiographically resectable pancreatic adenocarcinoma between January 2000 and December 2006. Preoperative carbohydrate antigen 19-9 (CA 19-9) values were assessed for their association with the presence of subradiographic unresectable disease.

Results

Four hundred ninety-one patients underwent staging laparoscopy. Resection was performed in 80% (n = 395). Of the 96 patients with unresectable disease, 75 (78%) had metastases either in the liver (n = 60) or peritoneum (n = 15). Preoperative CA 19-9 values were available for 262 of the 491 patients. Fifty-one of these patients had unresectable disease, of which 78% were due to distant disease. The median preoperative CA 19-9 value for patients who underwent resection was 131 U/ml versus 379 U/ml for those patients with unresectable disease (P = 0.003). A receiver operating characteristics (ROC) curve was developed for preoperative CA 19-9 value and tumor resectability. The statistically optimal cutoff value was determined to be 130 U/ml. Unresectable disease was identified in 38 of the 144 patients (26.4%) with a preoperative CA 19-9 ≥ 130 U/ml, and in 13 of the 118 patients (11%) with a CA 19-9 < 130 U/ml (P = 0.003). CA 19-9 values greater than 130 U/ml remained a predictor of tumor unresectability on multivariate regression analysis [hazard ratio (HR) 2.70, 95% confidence interval (CI) 1.34–5.44; P = 0.005].

Conclusion

In this study, preoperative CA 19-9 values were strongly associated with the identification of subradiographic unresectable disease. Preoperative CA 19-9 values may allow surgeons to better select patients for staging laparoscopy.
Literature
1.
go back to reference Catalano C, Laghi A, Fraioli F, et al. Pancreatic carcinoma: the role of high-resolution multislice spiral CT in the diagnosis and assessment of resectability. Eur Radiol 2003;13:149–56PubMedCrossRef Catalano C, Laghi A, Fraioli F, et al. Pancreatic carcinoma: the role of high-resolution multislice spiral CT in the diagnosis and assessment of resectability. Eur Radiol 2003;13:149–56PubMedCrossRef
2.
go back to reference Phoa SS, Reeder JW, Rauws EA, et al. Spiral computed tomography for preoperative staging of potentially resectable carcinoma of the pancreatic head. Br J Surg 1999;86:789–94PubMedCrossRef Phoa SS, Reeder JW, Rauws EA, et al. Spiral computed tomography for preoperative staging of potentially resectable carcinoma of the pancreatic head. Br J Surg 1999;86:789–94PubMedCrossRef
3.
go back to reference Jin Z, Li X, Cai L. Assessing the resectability of pancreatic ductal adenocarcinoma: a comparison of dual-phase helical CT arterial portography with conventional angiography. Chin Med Sci J 2001;16:40–5PubMed Jin Z, Li X, Cai L. Assessing the resectability of pancreatic ductal adenocarcinoma: a comparison of dual-phase helical CT arterial portography with conventional angiography. Chin Med Sci J 2001;16:40–5PubMed
4.
go back to reference Diehl SJ, Lehmann KJ, Sadick M, et al. Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology 1998;206:373–8PubMed Diehl SJ, Lehmann KJ, Sadick M, et al. Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology 1998;206:373–8PubMed
5.
go back to reference Callery MP, Strasberg SM, Doherty GM, et al. Staging laparoscopy with laparoscopic ultrasonography: optimizing resectability in hepatobiliary and pancreatic malignancy. J Am Coll Surg 1997;185:33–9PubMed Callery MP, Strasberg SM, Doherty GM, et al. Staging laparoscopy with laparoscopic ultrasonography: optimizing resectability in hepatobiliary and pancreatic malignancy. J Am Coll Surg 1997;185:33–9PubMed
6.
go back to reference Potter MW, Shah SA, McEnaney P, et al. A critical appraisal of laparoscopic staging in hepatobiliary and pancreatic malignancy. Surg Oncol 2000;9:103–10PubMedCrossRef Potter MW, Shah SA, McEnaney P, et al. A critical appraisal of laparoscopic staging in hepatobiliary and pancreatic malignancy. Surg Oncol 2000;9:103–10PubMedCrossRef
7.
go back to reference Karachristos A, Scarmeas N, Hoffman JP. CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg 2005;9:1286–92PubMedCrossRef Karachristos A, Scarmeas N, Hoffman JP. CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg 2005;9:1286–92PubMedCrossRef
8.
go back to reference Reddy KR, Levi J, Livingstone A, et al. Experience with staging laparoscopy in pancreatic malignancy. Gastrointest Endosc 1999;49:498–503PubMedCrossRef Reddy KR, Levi J, Livingstone A, et al. Experience with staging laparoscopy in pancreatic malignancy. Gastrointest Endosc 1999;49:498–503PubMedCrossRef
9.
go back to reference Friess H, Kleeff J, Silva JC, et al. The role of diagnostic laparoscopy in pancreatic and periampullary malignancies. J Am Coll Surg 1998;186:675–82PubMedCrossRef Friess H, Kleeff J, Silva JC, et al. The role of diagnostic laparoscopy in pancreatic and periampullary malignancies. J Am Coll Surg 1998;186:675–82PubMedCrossRef
10.
go back to reference White R, Winston C, Gonen M, et al. Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. J Am Coll Surg 2008;206:445–50PubMedCrossRef White R, Winston C, Gonen M, et al. Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. J Am Coll Surg 2008;206:445–50PubMedCrossRef
11.
go back to reference Fujioka S, Misawa T, Okamoto T, et al. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg 2007;14:539–44PubMedCrossRef Fujioka S, Misawa T, Okamoto T, et al. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg 2007;14:539–44PubMedCrossRef
12.
go back to reference Kilic M, Gocmen E, Tez M, et al. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg 2006;49:241–4PubMed Kilic M, Gocmen E, Tez M, et al. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg 2006;49:241–4PubMed
13.
go back to reference Lemenshow S, Hosmer DW. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiology 1982;115:92–106 Lemenshow S, Hosmer DW. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiology 1982;115:92–106
14.
go back to reference Soriano A, Castells A, Ayuso C, et al. Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am J Gastroenterol 2004;99:492–501PubMedCrossRef Soriano A, Castells A, Ayuso C, et al. Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am J Gastroenterol 2004;99:492–501PubMedCrossRef
15.
go back to reference Howard TJ, Chin AC, Streib EW, et al. Value of helical computed tomography, angiography, and endoscopic ultrasound in determining resectability of periampullary carcinoma. Am J Surg 1997;174:237–41PubMedCrossRef Howard TJ, Chin AC, Streib EW, et al. Value of helical computed tomography, angiography, and endoscopic ultrasound in determining resectability of periampullary carcinoma. Am J Surg 1997;174:237–41PubMedCrossRef
16.
go back to reference Valls C, Andia E, Sanchez A, et al. Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. Am J Roentgenol 2002;178:821–6 Valls C, Andia E, Sanchez A, et al. Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. Am J Roentgenol 2002;178:821–6
17.
go back to reference Velanovich V, Wollner I, Ajlouni M. Staging laparoscopy promotes increased utilization of postoperative therapy for unresectable intra-abdominal malignancies. J Gastrointest Surg 2000;4:542–6PubMedCrossRef Velanovich V, Wollner I, Ajlouni M. Staging laparoscopy promotes increased utilization of postoperative therapy for unresectable intra-abdominal malignancies. J Gastrointest Surg 2000;4:542–6PubMedCrossRef
18.
go back to reference Menack MJ, Spitz JD, Arregui ME. Staging of pancreatic and ampullary cancers for resectability using laparoscopy with laparoscopic ultrasound. Surg Endoscopy 2001;15:1129–34CrossRef Menack MJ, Spitz JD, Arregui ME. Staging of pancreatic and ampullary cancers for resectability using laparoscopy with laparoscopic ultrasound. Surg Endoscopy 2001;15:1129–34CrossRef
19.
go back to reference Conlon KC, Dougherty E, Klimstra DS, et al. The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg 1996;223:134–40PubMedCrossRef Conlon KC, Dougherty E, Klimstra DS, et al. The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg 1996;223:134–40PubMedCrossRef
20.
go back to reference Brooks AD, Mallis MJ, Brennan MF, et al. The value of laparoscopy in the management of ampullary, duodenal, and distal bile duct tumors. J Gastrointest Surg 2002;6:139–46PubMedCrossRef Brooks AD, Mallis MJ, Brennan MF, et al. The value of laparoscopy in the management of ampullary, duodenal, and distal bile duct tumors. J Gastrointest Surg 2002;6:139–46PubMedCrossRef
21.
go back to reference Vollmer CM, Drebin JA, Middleton WD, et al. Utility of staging laparoscopy in subsets of peripancreatic and biliary malignancies. Ann Surg 2002;235:1–7PubMedCrossRef Vollmer CM, Drebin JA, Middleton WD, et al. Utility of staging laparoscopy in subsets of peripancreatic and biliary malignancies. Ann Surg 2002;235:1–7PubMedCrossRef
22.
go back to reference Pisters PW, Lee JE, Vauthey JN, et al. Laparoscopy in the staging of pancreatic cancer. Br J Surg 2001;88:325–37PubMedCrossRef Pisters PW, Lee JE, Vauthey JN, et al. Laparoscopy in the staging of pancreatic cancer. Br J Surg 2001;88:325–37PubMedCrossRef
23.
go back to reference Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979;5:957–71PubMedCrossRef Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979;5:957–71PubMedCrossRef
24.
go back to reference Berger AC, Meszoely IM, Ross EA, et al. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol 2004;11:644–9PubMedCrossRef Berger AC, Meszoely IM, Ross EA, et al. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol 2004;11:644–9PubMedCrossRef
25.
go back to reference Safi F, Schlosser W, Falkenreck S, et al. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology 1998;45:253–9PubMed Safi F, Schlosser W, Falkenreck S, et al. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology 1998;45:253–9PubMed
26.
go back to reference Kang CM, Kim JY, Choi GH, et al. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 2007;140:31–5PubMedCrossRef Kang CM, Kim JY, Choi GH, et al. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 2007;140:31–5PubMedCrossRef
27.
go back to reference Safi F, Schlosser W, Kolb G, et al. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg 1997;1:106–12PubMedCrossRef Safi F, Schlosser W, Kolb G, et al. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg 1997;1:106–12PubMedCrossRef
28.
go back to reference Ferrone CR, Finkelstein DM, Thayer SP, et al. Perioperative CA 19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24:2897–902PubMedCrossRef Ferrone CR, Finkelstein DM, Thayer SP, et al. Perioperative CA 19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24:2897–902PubMedCrossRef
29.
go back to reference Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003;138:951–5; discussion 955–6PubMedCrossRef Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003;138:951–5; discussion 955–6PubMedCrossRef
30.
go back to reference Connor S, Bosonnet L, Alexakis N, et al. Serum CA 19-9 measurement increases the effectiveness of staging laparoscopy in patients with suspected pancreatic malignancy. Dig Surg 2005;22:80–5PubMedCrossRef Connor S, Bosonnet L, Alexakis N, et al. Serum CA 19-9 measurement increases the effectiveness of staging laparoscopy in patients with suspected pancreatic malignancy. Dig Surg 2005;22:80–5PubMedCrossRef
Metadata
Title
Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma
Authors
Shishir K. Maithel, MD
Stephen Maloney, MD
Corrine Winston, MD
Mithat Gönen, PhD
Michael I. D’Angelica, MD
Ronald P. DeMatteo, MD
William R. Jarnagin, MD
Murray F. Brennan, MD
Peter J. Allen, MD
Publication date
01-12-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 12/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0134-5

Other articles of this Issue 12/2008

Annals of Surgical Oncology 12/2008 Go to the issue